AlphAIAlphAI — Financial news for AI agents
tradingview.com$TEVA

Teva Insiders Sold Shares Worth Over $3M

Teva Pharmaceuticals officers sold shares. Dov sold 26,260 shares at $41.72 each, totaling $1.1M. Sabag sold 46,000 shares at $41.93 average, totaling $1.9M. Both retain significant holdings.

Original reporting
tradingview.com
Published Nov 6, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 10:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Teva Insiders Sold Shares Worth Over $3M — source image
Source · tradingview.com
Decision brief

The 30-second read

$TEVABearishLow
01

Why it matters

The disclosed sales represent a modest but notable reduction in insider holdings, potentially influencing short‑term sentiment.

02

Market read

Insider sell‑offs may trigger modest bearish sentiment for TEVA in the near term.

03

What to watch

The sales were at market prices and may not reflect negative outlook; upcoming product announcements could offset pressure.

Relevance 4/10Novelty 4/10Timing: post‑market release

Background

Teva Pharmaceutical Industries reported insider sales via SEC Form 4 filings.

Company-level read

Ticker impact

$TEVABearishMedium confidence
Context

Form 4 disclosed insider sales by Bergwerk Dov and Mark Sabag totaling over $3M.

Expected impact

likely downward pressure as the market prices in the insider sell-off

Evidence & confidence

Both insiders sold sizable blocks at market prices; such transactions often prompt traders to anticipate further declines.

Market effects

Sector

Minimal impact on the broader pharmaceutical sector.

Regional

Limited to U.S. markets where TEVA trades.

Global

Low

Counterpoint

What could challenge this read

Insider sales may be unrelated to fundamentals and could be routine portfolio rebalancing.

Key entities

  • Officer
    Bergwerk Dov

    Interim Chief Legal Officer, sold 26,260 shares.

  • Officer
    Mark Sabag

    Executive Vice President, International Markets Commercial, sold 46,000 shares.

Read at source← All news

Related articles

$TEVAMed

Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call Highlights

Teva Pharmaceutical (TEVA) reported a 2% revenue decline in Q3 2026, driven by a 16% drop in generics revenue. The company discontinued a Phase II study and faces challenges with AUSTEDO revenue due to pricing pressures. CEO Richard Francis and CFO Eli Kalif discussed gross margin expansion, IRA impact, and growth drivers like UZEDY, AJOVY, and WELTRUZA. Teva expects AUSTEDO to reach $2.5B in 2027 and over $3B at peak, despite litigation risks and biosimilar challenges.

finance.yahoo.com
$TEVAHighAI 8/10

H.C. Wainwright raises Teva Pharma stock price target to $54

H.C. Wainwright raised Teva's (NYSE:TEVA) price target to $54 from $52, citing strong Q3 results. Revenue was $4.395B (down 2% YoY, up 6% sequentially), and EPS was $0.86 (beating estimates). The company raised its full-year revenue guidance to $16.7B-$17.0B. Austedo, Ajovy, and Uzedy drove higher expectations. BofA Securities also raised its target to $48.

investing.com
$TEVAMed

Teva’s $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires

Teva and Samsung Bioepis agreed to a $420M deal for two biosimilars. Teva gains US rights to RENFLEXIS (infliximab-abda), which can be sold immediately, and ETICOVO (etanercept-ykro), blocked from US sales until 2029 due to patent disputes. The deal includes upfront, launch, and sales milestones. Teva aims to leverage its distribution network to boost RENFLEXIS's market share, while ETICOVO's launch is delayed by legal restrictions.

techtimes.com